INDV Indivior Pharmaceuticals Inc
Healthcare$37.81+0.75%ClosedMarket Cap: $4.72B
As of 2026-05-26
Valuation
P/E (TTM)
18.15
PEG
0.03
P/B
-32.67
P/S
3.63
EV/EBITDA
11.10
DCF Value
$2.65
FCF Yield
-3.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.1%
Operating Margin
33.3%
Net Margin
19.4%
ROE
-142.0%
ROA
21.0%
ROIC
85.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $317.0M | 87.4% | $137.0M | $89.0M | $— | — |
| Q4 null | $358.0M | 82.1% | $122.0M | $102.0M | $— | — |
| FY null | $1.24B | 80.1% | $265.0M | $210.0M | $— | — |
| Q3 null | $314.0M | 80.3% | $99.0M | $42.0M | $— | — |
| Q2 null | $302.0M | 82.8% | $72.0M | $18.0M | $— | — |
| Q1 null | $266.0M | 83.5% | $66.0M | $47.0M | $— | — |
| Q4 null | $299.0M | 92.3% | $96.0M | $59.0M | $— | — |
| FY null | $1.19B | 80.6% | $32.0M | $2.0M | $— | — |
| Q3 null | $307.0M | 77.5% | $4.0M | $4.0M | $— | — |
| Q2 null | $299.0M | 73.6% | $-118.0M | $-97.0M | $— | — |
| Q1 null | $284.0M | 86.6% | $75.0M | $61.0M | $— | — |
| Q4 2023 | $293.0M | 82.6% | $61.0M | $54.0M | $0.38 | — |